Triftazin-Darnitsya 0.2% / ml 10s solution for injection in ampoules

The instruction for use
of medicine for consumers
(summary insert)
Triftazin-Darnitsa
the Trade name
Triftazin-Darnitsa
the International unlicensed

name Trifluoperazin Lekarstvennaya a form
of 0.2% solution for injections
Structure
Active agent: 1 ml of solution contains 2 mg of Trifluoperazinum
of a hydrochloride.
Excipients: sodium citrate for injections, water for
injections.
The description
Transparent colourless or slightly yellowish liquid,
Indications
Schizophrenia, especially paranoid, simple with an apato-abulichesky syndrome, in its slow form, nuclear schizophrenia with the expressed hallucinatory paranoid phenomena and with psychopathy-like, neurosis-like, hypochondriac, senestopathetic symptomatology, periodic schizophrenia. The mental diseases proceeding with

crazy symptomatology and hallucinations: alcoholic hallucinations and paranoids, involutional psychoses, neurosises. Vomiting central, origins.

A route of administration and doses
the Initial dose makes 1-2 mg. Intramuscular repeated introduction is made in 4-6 hours, at more frequent injections the cumulation phenomena are possible. The daily dose is usually equal to 6 mg, in exceptional cases - 10 mg. At depressive and hallucinatory and depressive and crazy states Triftazin-Darnitsa apply together with antidepressants.
As antiemetic Triftazin-Darnitsa is appointed in doses of 1-4 mg a day. Treatment of Triftazinom-Darnitsa has to be strictly individualized depending on a course of the disease. Terms of treatment can be 3-9 months, and in some cases and moreover. To children at the age of 6 years on 1 mg 1-2 times a day are also more senior. If necessary
the dose can be increased up to 5-6 mg/days.
Side effect
At some patients is possible manifestation of side effect of drug. Namely:
- from the central nervous system: drowsiness, dizziness, dryness in a mouth, insomnia, an akathisia, diatonic extrapyramidal reactions, parkinsonism, a late disamneziya, an antipsychotic malignant syndrome, the phenomena of mental indifference, overdue reaction to external irritants,
- from an urinogenital system: an ischuria, decrease in potency, disturbance of an ejaculation, a priapism, an oliguria,
- from an endocrine system: hypo - or a hyperglycemia, a glucosuria, a dysmenorrhea, a genikomastiya, increase in body weight,
- from digestive tract: anorexia, bulimia, nausea, vomiting, diarrhea, constipations, a gastralgia, cholestatic jaundice,
- from sense bodys: accommodation paresis, a retinopathy, a cataract and corneas,
- from blood: thrombocytopenia, agranulopitoz, anemia, a pancytopenia,
- from a cardiovascular system: tachycardia, a lowering of arterial pressure (orthostatic hypotension),
- allergic reactions: skin rash, a small tortoiseshell, a Quincke's disease, an acute anaphylaxis,
- others: fotodermiya.
Contraindications
Hypersensitivity to drug components, dekompensiro-bathing heart failure, the profound arterial hypotension. Coma of any etiology. The progressing general diseases of a head and spinal cord. Pregnancy and period of a lactation. Stenocardia.

Breast cancer. Closed-angle glaucoma. Functional renal and liver failure. A peptic ulcer of a stomach and duodenum during aggravation. Epilepsy, Parkinson's disease. Disturbance of the mechanism of the central regulation of breath (especially at children), a syndrome to Reja. Cachexia. Myxedema. Prostate hyperplasia. The pathological changes of blood connected with hemopoiesis disturbance.
Interaction with other medicines
the Effects of drug amplify at simultaneous use by the sosredstvo oppressing functions of the central nervous system. Effects at a concomitant use of ethanol Vzaimnousilivatsya. Gipotenzivnyeeffekta of drug strengthen r-adrenoblockers. Effects are preparataoslablyat by a levodopa and Phenaminums. Drug reduces effektivnostprotivoepileptichesky means. Anti-thyroid drugs
increase risk of developing an agranulocytosis. At co-administration
with astimizoly, Disopyramidum, erythromycin, procaineamide risk of developing tachycardia increases. At combined use with tricyclic antidepressants, Maprotilinum, MAO inhibitors - lengthening and strengthening of sedative and anticholinergic effects is possible. At combined use with drugs of lithium strengthening of extrapyramidal disturbances, early approach of symptoms of intoxication lithium is possible. Co-administration with adrenomimetika and sympathomimetics can lead to a paradoxical lowering of arterial pressure.
The feature of use
during drug treatment needs to abstain from control of motor transport and from occupations potentially dangerous types of activity demanding the high speed of psychomotor reactions. Use of drug can cause
manifestation of irreversible dyskinesia in elderly patients. It is not recommended
to take alcohol during drug treatment.
At emergence of symptoms of late dyskinesia or an antipsychotic
malignant syndrome the administration of drug should be stopped.
At drug treatment it is necessary to avoid influence of high
temperature (possibly thermal control disturbance).
Overdose.
The overdose is shown by dyskinesia, a dysarthtia, drowsiness and a stupor. In hard cases the coma is possible.
Treatment. In respiratory depression carry out artificial ventilation of the lungs, oxygen therapy. Correction of acid-base equilibrium, water and electrolytic balance, artificial diuresis.
i
a release Form
On 1 ml of solution for injections in an ampoule, on 10 ampoules in packing.

To Store storage conditions in the inaccessible for children, protected from light place, at a temperature not above 25 °C.
Expiration date.
4 years. Not to use after the expiry date specified on packing.
Prescription status
According to the prescription.

CJSC Pharmaceutical Firm Darnitsa producer.

Address Ukraine 02093 Kiev, Borispolskaya St., 13.